Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA
Ascentage Pharma Group International (NASDAQ:AAPG) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating on the stock.
Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025
Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature’s Signal Transduction and Targeted Therapy
Ascentage Pharma Group International (NASDAQ:AAPG) was given a new $51.00 price target on by analysts at Truist Financial Corporation.